N,N'-(decane-1,10-diyldi-1(4H)-pyridyl-4-ylidene)bis(octylammonium) dichloride

Endpoint summary

Description of key information

The LD50 of octenidine dihydrochloride in rats was 800 mg/kg bw, in rabbits the LD50 lies presumably between 250 and 800 mg/kg bw. Poisoning symptoms were independent of the species tested and included ataxia, dyspnoea, reduced motor activity, loose or dark stools. Further, reduced body weight gain or body weight loss was observed in the post exposure period. At necropsy, hyperaemia and ulcers of the stomach were seen as well as adhesions of the stomach to the liver. It is likely that these symptoms are the result of the antiseptic effects of octenidine dihydrochloride in the gastroinintestinal tract resulting in a loss of intestinal flora, and thus malnutrition and increased intestinal gas production.

Key value for chemical safety assessment

Acute toxicity: via oral route

Link to relevant study records

Reference

Endpoint:

acute toxicity: oral

Type of information:

experimental study

Adequacy of study:

key study

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

comparable to guideline study with acceptable restrictions

Remarks:

only 7 day observation period, rats were younger than recommended

Qualifier:

equivalent or similar to guideline

Guideline:

OECD Guideline 401 (Acute Oral Toxicity)

GLP compliance:

no

Test type:

standard acute method

Limit test:

no

Specific details on test material used for the study:

Test material Octenidine dihydrochloride
Lot/Batch number No data
Specification Win 41,462-2(b), We-Z-142
Description White powder

Species:

rat

Strain:

Sprague-Dawley

Sex:

male

Details on test animals or test system and environmental conditions:

Age/weight at study initiation: Adult/100-130 g, Mean 116 g

Route of administration:

oral: gavage

Vehicle:

other: Viscous suspension in 1% gum tragacanth

Doses:

Concentration 500-3160 mg/kg bw
Concentration in vehicle 5-25%

No. of animals per sex per dose:

10

Control animals:

yes

Details on study design:

- Duration of observation period following administration: 7 days
- Frequency of observations and weighing: daily
- Necropsy of survivors performed: yes/no
- Other examinations performed: clinical signs, body weight,organ weights, histopathology, other:

Statistics:

not reported

Sex:

male

Dose descriptor:

LD50

Effect level:

800 mg/kg bw

Based on:

test mat.

Clinical signs:

other: Symptoms of toxicity were mainly observed among rats that died later, and included wet matted fur, dyspnea, ataxia, partial to complete absence of motor activity, and brown exudates around eyes and nares; exept for the wet matted fur, observed only on the

Gross pathology:

In 8 of the 35 rats dying during the study the lungs were congested throughout; pitted areas and apparent thickening of the glandular portion of the stomach and adhesions of the stomach to the liver were seen in 12 of the 35 (2 at 794, 6 at 1260 and 4 at 2000 mg/kg bw); 2 of these stomachs contained black material, possibly clotted blood; in another rat that died, a large area of congestion was observed in the glandular portion of the stomach.
In those rats surviving at 7 days no gross tissue changes attributable to the drug were observed except of adhesions of stomach to the liver and spleen, and thickening, perforations, and pitted areas in the glandular portion of the stomach found in 2 rats of the 794 mg/kg bw group.

Other findings:

At 24 h, mean body weight gains of 12% and 7% had occurred in the control and 500 mg/kg bw groups, there was no change in the rats dosed with 794 mg/kg bw and there were losses of 5%, 8% and 9%, respectively, in the 1260, 2000 and 3160 mg/kg bw groups; at day 7, total body weight gains of 41%, 36% and 27%, respectively, were reported for the control, the 500 and 794 mg/kg bw groups, in the 1260, 2000 and 3160 mg/kg bw groups were no survivors

Interpretation of results:

Category 4 based on GHS criteria

Conclusions:

The LD50 of octenidine dihydrochloride in rats was 800 mg/kg bw.

Endpoint conclusion

Endpoint conclusion:

adverse effect observed

Dose descriptor:

LD50

Value:

800 mg/kg bw